The ADA genes encode factors which are proposed to function as transcriptional coactivators. Here we describe the cloning, sequencing, and initial characterization of a novel ADA gene, ADA1. Similar to the previously isolated ada mutants, ada1 mutants display decreases in transcription from various reporters. Furthermore, ADA1 interacts with the other ADAs in the ADA/GCN5 complex as demonstrated by partial purification of the complex and immunoprecipitation experiments. We estimate that the complex has a molecular mass of approximately 2 MDa. Previously, it had been demonstrated that ada5 mutants displayed more severe phenotypic defects than the other ada mutants (G. A. Marcus, J. Horiuchi, N. Silverman, and L. Guarente, Mol. Cell. Biol. 16:3197-3205, 1996; S. M. Roberts and F. Winston, Mol. Cell. Biol. 16:3206-3213, 1996). ada1 mutants display defects similar to those of ada5 mutants and different from those of the other mutants with respect to promoters affected, inositol auxotrophy, and Spt ؊ phenotypes. Thus, the ADAs can be separated into two classes, suggesting that the ADA/GCN5 complex may have two separate functions. We present a speculative model on the possible roles of the ADA/GCN5 complex.
RNA polymerase II (Pol II)-dependent transcription in eukaryotes requires general transcription factors and gene-specific transcriptional activators. The general factors include Pol II itself, the TATA binding protein (TBP), TFIIB, and other factors required for preinitiation complex formation at promoters. Activators bind to upstream activating sequences (UAS) or enhancers, which can be hundreds of base pairs upstream from the site of initiation of transcription, and stimulate transcription through their activation domains. In addition to these two types of factors, a third type whose members are referred to as mediators, coactivators, or adaptors has been isolated (3, 32, 44) . These have been proposed to function by several mechanisms, including bridging interactions between activator proteins and basal factors and counteracting of the repressive effects on transcription by nucleosomes. Many factors believed to belong to this coactivator group form large heteromeric complexes. For example, the SWI/SNF complex is approximately 2 MDa in size (11, 40, 60) and functions by countering chromatin-mediated repression (14, 27) . The suppressor of RNA polymerase B (SRB) complex is required for robust activated and basal transcription and interacts with basal factors to form an RNA Pol II holoenzyme complex (25, 35, 58) . The TFIID complex consists of basal transcription factor TBP and associated TAF proteins which are thought to be required for activated transcription (15, 51, 59) .
Two other groups of factors which seem to function as adaptors or coactivators, the SPTs and the ADAs, were identified genetically in Saccharomyces cerevisiae. The SPT genes were isolated as suppressors of the auxotrophies resulting from transposon insertions at the promoters of various biosynthetic genes. The SPT genes fall into two classes based upon the insertions that they suppress and upon various other genetic and molecular characteristics (61) . One class is the histone class, which includes SPT4, SPT5, SPT6, SPT11, and SPT12. SPT11 and SPT12 encode histones H2A and H2B, respectively. SPT4, SPT5, and SPT6 also encode negative regulators of transcription that form a complex and that are thought to be functionally related to H2A and H2B (57) . The second class, the TBP class, includes SPT3, SPT7, SPT8, SPT15, and SPT20. SPT15 encodes TBP, while the others encode products which are thought to interact with TBP and to play a role in transcriptional-initiation site selection (16, 17, 61) .
The ADA genes were isolated as suppressors of GAL4-VP16 toxicity (4) . When GAL4-VP16 is overexpressed, it is thought to kill yeast cells by sequestering the general transcription factors away from productive transcription complexes. Therefore, mutations that suppress toxicity may be in genes encoding factors that mediate the interaction between the general factors and activation domains. The ada mutants fell into five complementation groups, four of which have been characterized, ADA2, ADA3, GCN5, and ADA5 (4, 37, 38, 43) . GCN5 had been previously isolated as a gene whose product was a factor required for full transcriptional activation by GCN4 (21) . ADA3 has been subsequently isolated as NGG1, a gene whose product is required for glucose repression (5, 6) .
ADA2, ADA3, and GNC5 are all required for full transcriptional activation by a subset of activators, including GAL4-VP16 and GCN4 (4, 38, 43) . This is consistent with a model in which these ADAs function as adaptors for a subset of activators. Also, mutations in the three genes yield similar phenotypes, such as temperature sensitivity and slow growth. Mutants carrying null alleles of any two of the three genes display phenotypes identical to those of single mutants (20, 38) . It has been demonstrated that ADA2, ADA3, and GCN5 interact to form a complex (12, 29, 38) .
ADA5 is similar to the other ADAs except that mutations result in some broader transcriptional defects (37, 45) . For example, the ADH1 promoter is not affected by mutations in ADA2, ADA3, or GNC5 but is reduced in ada5 mutants. Furthermore, ADA5 has been shown to be identical to SPT20 linking the ADA genes and the SPT genes (45) . The other ADAs have not been isolated as spt mutants and do not display Spt Ϫ phenotypes. Despite these differences, ⌬ada5 ⌬ada3 mutants do not demonstrate any phenotypes more severe than that of a ⌬ADA5 mutant. Furthermore, there is evidence that ADA5 interacts with ADA3 (37), suggesting that it too is part of an ADA/GCN5 complex.
Recently, a functional role for the ADA/GCN5 complex has been suggested. A histone acetyltransferase activity has been purified from Tetrahymena macronuclei (7). The gene responsible for this activity was cloned and was determined to be a homolog of GCN5 (10) . Yeast GCN5 has also been shown to have histone acetyltransferase activity. Combined with data that ADA2 and ADA5 interact with activators (2, 37, 39, 55) , this suggests that the role of the ADA/GCN5 complex may be to acetylate nucleosomes at transcriptionally active sites (8) .
In this study, we describe the cloning and characterization of a novel ADA gene, ADA1. We present evidence that ADA1 is part of a large ADA/GCN5 complex and that ada1 mutants display phenotypes similar to that of ada5 and broader than those of ada2, ada3, and gcn5 mutants. Thus, although the ADA proteins bind to form a complex, they can be separated into two classes, suggesting that the ADA/GCN5 complex may have a second function in addition to histone acetylation.
MATERIALS AND METHODS
Strains and media. Strains used in this study are shown in Table 1 . BWG1-7a, 1-7a⌬ada1, and 1-7a⌬ada2 were used for purification and immunoprecipitation experiments. BWG1-7a, 1-7a⌬ada1, PSY316, and 316⌬ada1 were used for ␤-galactosidase assays. Inositol studies were performed with PSY316 and PSY316 in which the appropriate ADA gene was disrupted. Strains FY56, FY710, and FY630, used to determine Spt phenotypes, were gifts from S. Roberts and F. Winston. Disruptions of ADA1 in yeast cells were generated by transforming the appropriate strains with pADA1KO (described below) that had been linearized with XhoI. ADA3 was deleted with pADA3KO (38) . Disruptions were verified by Southern analysis.
Rich, synthetic complete, and synthetic minimal media were prepared as previously described (53) .
Cloning and sequencing of ADA1. Three original clones complementing the slow-growth, morphological-defect, and GAL4-VP16-resistance phenotypes of the ada1-1 mutant (4) were originally isolated. One clone, YCP50ADA1, had an 11-kb insert. Two others had identical 16-kb inserts. Physical mapping with restriction enzymes revealed that these clones overlapped over a region of 5.7 kb. This region had a convenient HindIII site. By using a second HindIII site in the vector (YCP50) and a third in a nonoverlapping region in YCP50ADA1, the 5.7-kb region was split into two fragments which were separately subcloned into YCP50. Neither subclone complemented the slow-growth phenotype of the ada1-1 mutant, suggesting that the relevant gene had been cut in half. The HindIII fragments were subcloned into pBluescript (Stratagene) and sequenced from the internal HindIII site. Sequencing was performed by the dideoxy chain termination method (49) . Further sequence was obtained by either subcloning convenient restriction fragments into pBluescript or using custom synthetic oligonucleotide primers. This revealed an open reading frame of 488 codons (later verified as ADA1) with an internal HindIII site.
Plasmid constructions. PCR primers were designed such that the coding region of ADA1 could be amplified with BamHI and AflIII sites on the 5Ј end and a six-histidine tag followed by a stop codon and a BamHI site on the 3Ј end of the gene. The PCR product was digested with BamHI and ligated into the BamHI site of pBluescript to generate BluescriptADA1. The BluescriptADA1 BamHI fragment was cloned into the BglII site of DB20LeuBgl (4) to generate DB20LADA1.
To verify that the cloned ADA1 gene actually corresponded to the gene that was mutated in the ada1-1 strain, it was necessary to mark the genomic locus of the cloned gene. The BamHI fragment from DB20LADA1 which contained the cloned gene under control of the ADH1 promoter was inserted into the BamHI site in pRS306 (54), a URA3-marked integrating plasmid. This construct was digested with BclI to direct integration to the cloned locus and was used as described in Results.
The disruption construct of ADA1, pADA1KO, was generated in several steps. Vector pUC19Xho-Hind was constructed by inserting an XhoI linker into the SmaI site of pUC19 and destroying the HindIII site by cutting, filling in with Klenow fragment, and ligating. A 5.4-kb XhoI fragment containing the coding and flanking sequences of ADA1 was digested from YCP50ADA1 and ligated into the XhoI site of pUC19Xho-Hind. This was subsequently digested with HindIII and EcoRV, filled-in with Klenow fragment, and ligated to a BglII linker. The hisG-URA3 cassette from pNKY51 (1) was ligated into the BglII site. This construct disrupts ADA1 between the codons for amino acids 113 and 408.
For recombinant expression of ADA1, the bacterial expression vector pUHE24.2⌬CAT (38) was used. The ADA1 coding region fused to a six-histidine tag was digested from BluescriptADA1 with AflIII and BamHI. This fragment was cloned into the NcoI and BamHI sites of pUHE24.2⌬CAT to generate pUHE24.2ADA1.
For recombinant expression of GCN5, the GCN5 coding sequence was amplified by PCR with primers GCN5N and GCN5C (38) . The product was digested with EcoRI and NotI and cloned into the EcoRI and NotI sites of pET28a (Novagen). The resulting plasmid, pET28a-EcoGCN5, could be used to express a carboxyl-terminal fragment of GCN5 with a six-histidine tag at its aminoterminal end.
To make plasmid pPADA26HIS, pDB200CADA26HIS, an ARS-CEN derivative of pADA26HIS (55) , was digested with SpeI, filled in with T4 DNA polymerase, and then digested with AflII. The fragment that contained the C-terminal one-third of ADA2 fused to a six-histidine tag and that was followed by the ADH1 terminator was purified and cloned into pNS3.8 (4) that had been digested with AflII and MscI. This created a plasmid which contained the ADA2 promoter expressing the ADA2-six-histidine fusion gene followed by the ADH1 terminator.
Yeast manipulations. Transformations were performed by the lithium acetate method (53) . For ␤-galactosidase assays, cells were grown to an optical density at 600 nm of approximately 1.0 and activity was measured in glass bead extracts as previously described (46) . Cells were grown in synthetic complete medium lacking uracil. For HIS(2)14x2 and HIS(1)66 activity, cells were induced in minimal media complemented only for the auxotrophies of the yeast for 8 h. ␤-Galactosidase activity was measured as nanomoles per minute per milligram of protein.
Reporters used were pLG⌬AluXho (22) for CYC1 UAS1, which binds the activator HAP1; pLG265UP1 (18) for CYC1 UAS2, which binds the HAP2/3/4/5 heterotetrameric activator; HIS (1)66 (26) and HIS (2)14x2 (26), which bind GCN4; pCP0 (50) , which contains the ADH1 promoter; and pdAT2 (36) , which contains the thymidine-rich UAS of the DED1 gene. Other general yeast techniques were performed according to standard protocols (23) .
Generation of antisera. pUHE24.2ADA1 was transformed into AG115 (30) cells. Cells were grown to an optical density of 0.5, induced with 2 mM isopropyl-␤-D-thiogalactopyranoside, and grown for another 2 h. Cells were lysed by sonication, and the insoluble material, which contained recombinant ADA1 fused to a six-histidine tag, was resuspended in 8 M urea. Recombinant ADA1 was purified on a Ni-nitrilotriacetic acid (NTA) agarose column (Qiagen) as recommended by the manufacturer.
To obtain polyclonal antisera to ADA1, 1 mg of recombinant ADA1 was dialyzed into 2 ml of phosphate-buffered saline solution, mixed with adjuvant (RIBI ImmunoChem Research, Inc.), and injected into two rabbits according to standard protocols (24) . After several boosts, antibodies to ADA1 were purified from crude serum by binding to immunoblots of recombinant ADA1 and eluting at pH 2.5 or by binding and eluting from recombinant ADA1 cross-linked to cyanogen bromide-activated Sepharose beads.
In order to generate antibodies to GCN5, a carboxyl-terminal fragment of GCN5, tagged with six histidines, was purified in a manner similar to that for ADA1 above, except that plasmid pET28a-EcoGCN5 and strain BL21:DE3 (Novagen) were used. The eluate from the Ni-NTA agarose column was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and acrylamide slices containing the GCN5 protein fragment were VOL. 17, 1997 ADA1 AND THE ROLES OF THE ADA/GCN5 COMPLEXlyophilized and resuspended in phosphate-buffered saline. Antibodies to GCN5 were generated as described for ADA1 except that 400 g of protein was injected into each rabbit. Antibodies to ADA2 (38) , ADA3 (37), ADA5 (37), TBP, and TFIIB (33) have been described previously. Extracts and fractionation. The purification of the ADA/GCN5 complex was performed in 1-7a⌬ada2 (4) carrying pPADA26HIS. Cells were grown in minimal media to yield an approximate wet weight of 500 g. Preparation and fractionation of whole-cell extract on a Bio-Rex 70 column (5 by 10 cm) were performed as described by others (52) except elutions were performed with 250, 600, and 1,200 mM potassium acetate. Elutions were analyzed for the presence of ADA2 and ADA3 proteins by Western blotting. The relevant fractions from the 600 mM potassium acetate elutions were pooled and dialyzed against a buffer containing 20 mM HEPES (pH 7.6), 10% glycerol, 300 mM potassium acetate, 10 mM ␤-mercaptoethanol, and protease inhibitors. This material was then bound to an Ni-NTA agarose column (1.5 by 10 cm) and eluted with an imidazole gradient. Fractions enriched in ADA2 and ADA3 were pooled and diluted into buffer H (20 mM HEPES [pH 7.6], 10% glycerol, 1 mM dithiothreitol, 1 mM EDTA, protease inhibitors) to a final salt concentration of 100 mM potassium acetate. This material was then fractionated over a Poros HQ-20 column (4.6 by 100 mm) (PerSeptive Biosystems) with an elution gradient from 100 to 1,500 mM potassium acetate of 10 column volumes by using the BioCAD Sprint apparatus (PerSeptive Biosystems). Fractions that contained the peak of ADA proteins were pooled and loaded onto a Superose 6 HR 10/30 gel filtration column (Pharmacia Biotech). The column was then washed with buffer H containing 300 mM potassium acetate, and fractions were collected. As a control for determining the approximate molecular weight of the ADA/GCN5 complex, protein size standards (Bio-Rad) were fractionated on the Superose 6 column under identical conditions.
For quantifying purification, a densitometer (LKB) was used to measure the relative band intensities on immunoblots of ADA2, ADA3, and ADA1.
Immunoprecipitations. Preparation and fractionation of extracts of BWG1-7a and 1-7a⌬ada1 were performed as described previously (37) . Cross-linking of antisera to protein A-Sepharose beads and immunoprecipitation experiments were also performed according to published methods (11) except that 1 ml of the 600 mM eluate from the Bio-Rex 70 column was used for the precipitations and except that bound material was eluted off the antisera-coated beads with 20 l of 50 mM glycine (pH 2.5), neutralized with 3 l of 1 M Tris (pH 7.5), and mixed with 4ϫ SDS-PAGE loading buffer.
Nucleotide sequence accession number. The sequence of ADA1 has been assigned GenBank accession no. U76735; that of the sequence of HFI1, a gene identical to ADA1, is U41324 (19) .
RESULTS
Cloning and sequencing of ADA1. ada mutants were isolated from a screen for GAL4-VP16-resistant mutants as previously described (4), with the exception that the first ada1 allele, ada1-1, was isolated from nonmutagenized cells. The ada1 mutants isolated have severe slow-growth defects and morphological changes (28) . These phenotypes are recessive. We therefore used the slow-growth phenotype of ada1-1 to isolate complementing clones from a yeast genomic library on an ARS-CEN-containing vector (4, 42) . Three overlapping clones which not only restored wild-type growth but also restored wild-type morphology and sensitivity to overexpressed GAL4-VP16 were isolated. By analyzing the complementation of subclones and sequencing, a putative open reading frame of 488 codons was identified (see Materials and Methods). The putative open reading frame was amplified by PCR and cloned into an episome under the control of the ADH1 promoter (see Materials and Methods). This construct also complemented the slow-growth phenotype, restored wild-type morphology, and restored sensitivity to GAL4-VP16 overexpression. To verify that the cloned gene corresponded to ADA1, the URA3 marker was integrated at the cloned locus in a wild-type strain (see Materials and Methods) and mated to ada1-1. The resultant diploid was sporulated, and in six of six four-spore tetrads tested, resistance to GAL4-VP16 toxicity segregated 2:2 in opposition to the Ura ϩ phenotype. It was determined through database searches that a gene identical to ADA1, termed HFI1, had been cloned (19) . There are no other genes with any significant homologies to ADA1.
ADA1 was deleted in yeast cells as described in Materials and Methods. The deletion mutant was similar to ada1 other mutants with respect to slow growth and resistance to GAL4-VP16 toxicity. Both phenotypes were fully complemented by the cloned gene. The morphological changes for ada1 mutants mentioned above were determined to be strain specific. Disrupting ADA1 in BWG1-7a resulted in extremely elongated cells, similar to the morphology of the original ada1-1 mutant, which was in a BWG1-7a background. Disrupting ADA1 in PSY316 resulted in a slight change in cell morphology which was much less apparent than that in BWG1-7a.
ada1 mutants display transcriptional defects. Consistent with a model in which the ADA proteins function as transcriptional coactivators or adaptors, the ADAs isolated previously have specific defects in transcription (4, 37, 38, 43) . In order to determine whether ⌬ada1 strains were also defective for transcription from certain activators, ␤-galactosidase assays were performed on wild-type and ⌬ada1 strains transformed with various reporters. As demonstrated in Table 2 , ⌬ada1 strains show decreased activity from several reporters. The activities of reporters which bind activators HAP1 (CYC1 UAS1) and HAP2/3/4/5 (CYC1 UAS2UP1) were reduced 21-and 9-fold, respectively, and those of reporters which bind the activator GCN4, HIS(1)66 and HIS(2)14x2, were reduced 15-and 34-fold, respectively. The activity of the ADH1 reporter was also reduced fivefold in a ⌬ada1 strain. This is of particular interest because the ⌬ada2, ⌬ada3, and ⌬gnc5 strains do not show this decrease (4, 38) , while ⌬ada5 strains do (37) . These results suggest that the ADA genes can be separated into two classes based upon transcriptional differences. The activity of a reporter containing the thymidine-rich sequences of the DED1 gene as a UAS, dAdT, was not reduced in a ⌬ada1 strain. In fact, activity may have been slightly elevated. This argues that it is not a general defect in transcription that occurs in ⌬ada1 strains but rather specific defects that affect only a subset of promoters.
ada1 mutants are auxotrophic for inositol and display Spt ؊ phenotypes. Mutations in many factors that are thought to be coactivators result in inositol auxotrophy. These include the SRB genes (34), the SWI/SNF genes (41), and some SPT genes, including ADA5/SPT20 (45) . In order to determine whether deleting ADA1 resulted in inositol auxotrophy, various strains were grown on plates lacking inositol. As shown in Fig. 1 , a ⌬ada1 strain does not grow on media lacking inositol, whereas ⌬ada2, ⌬ada3, and ⌬gcn5 strains do. This further links ADA1 to ADA5 phenotypically and separates them from ADA2, ADA3, and GCN5. To determine whether ada1 mutants displayed other phenotypes similar to that of ada5/spt20 mutants, we tested whether ⌬ada1 strains displayed an Spt Ϫ phenotype. ADA1 was disrupted in strain FY56, which contains ␦ element insertions at the HIS4 and LYS2 loci. As demonstrated in Fig. 2A , a ⌬ADA1 mutant was indeed able to suppress the his4-912␦ and lys2-128␦ alleles present in yeast strain FY56. In contrast, a ⌬ADA3 mutant was unable to suppress these alleles, further delineating the two classes of ADA genes. As a positive control, strain FY710 (hta1 htb1⌬) was also able to suppress both the his4-912␦ and lys2-128␦ alleles.
As mentioned previously, the SPT genes can be separated into two classes: the histone class and the TBP class. Paradoxically, ADA5 had been isolated as an SPT of the TBP class (45), while GCN5 has been shown to acetylate histones (10) . Thus, we were interested in knowing whether ADA1 is of the TBP or histone class of SPTs. Since the his4-912␦ and lys2-128␦ alleles do not distinguish between the two classes, ADA1 and ADA3 were disrupted in strain FY630, which contains his4-917␦, an allele specifically suppressed by the TBP class but not the histone class. As demonstrated in Fig. 2B , a mutant with a deletion of ADA1 was able to suppress the his4-917␦ allele while a mutant with a deletion of ADA3 was not. This demonstrates that ADA1 is of the TBP class of SPT genes. FIG. 1 . Inositol phenotype of a ⌬ada1 strain. 316⌬ada1, 316⌬ada2, 316⌬ada3, GMy27 (316⌬gnc5), and, as a positive control, 316⌬ada1 transformed with YCP50ADA1 (⌬ada1ϩADA1) were grown on synthetic complete media lacking inositol (ϪInositol) and on an identical plate on which 200 l of 200 mM inositol had previously been spread (ϩInositol).
FIG. 2. Spt
Ϫ phenotype of a ⌬ada1 strain. (A) The indicated strains were streaked on synthetic complete media (Complete) or media lacking lysine (Ϫlysine) or histidine (Ϫhistidine) to determine whether they suppressed the his4-912␦ and lys2-128␦ alleles present. FY710, for which the histone hta1-htb1 locus is disrupted, was used as a positive control. (B) The indicated strains were patched on synthetic complete media (Complete) or on media lacking histidine (Ϫhistidine) to determine whether they suppressed the his4-917␦ allele, which is specifically suppressed by mutants in the TBP class of SPTs.
VOL. 17, 1997 ADA1 AND THE ROLES OF THE ADA/GCN5 COMPLEXPartial copurification of an ADA complex. 1-7a⌬ada2 was transformed with pPADA26His, a plasmid which expresses a six-histidine-tagged version of ADA2 from its own promoter and which fully complements a deletion of the gene (56) . The resulting strain was grown in minimal media and was used to make a whole-cell extract which was fractionated over a BioRex 70 column (see Materials and Methods). After step elution with potassium acetate, the ADA proteins were detected by Western blot analysis in two fractions: the 600 mM fraction and the 1,200 mM fraction. The 600 mM fraction contained about 60% of the ADA proteins, and the 1,200 mM fraction accounted for the remainder (56) . We estimate that both the 600 and 1,200 mM eluent fractions represent a 10-fold purification of the ADA/GCN5 complex (Table 3) .
Next, the 600 mM eluent was bound to a Ni-NTA agarose column. The Ni-NTA column was eluted with a gradient of imidazole, and the ADA proteins were quantitatively recovered in the peak fractions of the eluent. This step represented only a 1.6-fold purification of the ADA/GCN5 complex (56) because a relatively large fraction of proteins in the yeast extract bound to the column under the conditions we used.
The peak fractions eluted from the Ni-NTA column were fractionated on an HQ-20 anion-exchange column and were eluted with a gradient of potassium acetate. As shown in Fig.  3 , cofractionation of ADA1, ADA2, ADA3, GCN5, and ADA5 was observed. The peak of the ADA/GCN5 complex eluted from the column at approximately 1.1 M potassium acetate. The ADA proteins were purified approximately 160-fold in the peak fractions from this column ( Table 3 ). The fractions eluted from the HQ-20 column were also probed for the basal transcription factor, TBP. While TBP was present in the material loaded onto the column, it did not cofractionate with the ADA complex (Fig. 3) and, in fact, flowed through the column. Fractions from the HQ-20 column were also probed with antibodies to other transcription factors. TFIIB and TFIIE behaved similarly to TBP and flowed through the column, while SRB4, SRB5, SWI3, and TFIIH fractionated together, eluting prior to the ADA/GCN5 complex (56) .
Finally, the fractions from the HQ-20 column containing the peak amounts of ADA proteins were pooled and subjected to fractionation on a Superose 6 gel filtration column. Again, all ADA proteins cofractionated over this column (Fig. 4) . A comparison of the elution profiles of the ADA proteins with those of known protein standards indicated that the ADA proteins eluted at an approximate molecular mass of 2 MDa. Use of the sizing column resulted in an 18-fold purification of the ADA proteins, bringing the total purification to approximately 2,880-fold (Table 3 ). These data suggest that the ADA gene products, including GCN5, form a complex in yeast.
Fractionation of the 1,200 mM potassium acetate elution from the Bio-Rex 70 column on either an HQ-20 column or a Superose 6 column also resulted in cofractionation of all five ADA proteins (56) .
ADA1 interacts with the ADA complex by immunoprecipitation. In order to verify that ADA1 interacts with the other ADAs, whole-cell extracts were made from wild-type and ⌬ada1 strains grown in rich media. The extracts were then passed over a Bio-Rex 70 column, and the flowthrough and 250, 600, and 1,200 mM potassium acetate elutions were examined by Western blotting. As demonstrated in Fig. 5A , ADA1 eluted from this column in a profile identical to that of ADA3. The band that is seen in the 600 mM fraction of the ⌬ada1 strain is a background band that migrated at a slightly higher molecular weight than that of ADA1 (compare wt and ⌬ada1 START lanes in the ADA1 Western blot of Fig. 5B ). In contrast to the partial purification of the ADA/GCN5 complex   FIG. 3 . Cofractionation of ADA1, ADA2, ADA3, GCN5, and ADA5 over an HQ-20 anion-exchange column. All panels show immunoblots of fractions from the HQ-20 column eluted with a potassium acetate gradient. The onput (OP) and flowthrough (FT) and every odd-numbered fraction between fractions 13 and 23 were probed with antibodies to the indicated proteins. The band recognized by the GCN5 antibody ran slightly faster than expected. It is possible that GCN5 was slightly degraded in our extracts .   FIG. 4 . Cofractionation of the ADA proteins over a Superose 6 gel filtration column. Aliquots of the onput (OP) to the column and the indicated fractions were trichloroacetic acid precipitated and analyzed by Western blotting. Antibodies to the indicated proteins were used to probe the blots. Aliquots corresponded to 3% of the onput and 25% of the fractions. a The fold purification for a column is the ratio of the yield divided by the protein in the pooled fractions of the column to that of the previous column. The total fold purification at a particular column step is the product of that column's fold purification and the total fold purification for the previous column.
b The Superose 6 HR column was an analytical column with a low capacity and yield.
described above, some ADA1 and ADA3 was observed in the flowthrough fraction. The flowthrough fraction was run over a Superose 6 column, and all five ADA proteins cofractionated, as determined by Western blotting (28) , suggesting that the column residue may have been limiting in this second preparation.
ADA1 was immunoprecipitated from the 600 mM potassium acetate elutions from the Bio-Rex 70 column with ADA1 antibodies cross-linked to protein A-Sepharose beads. As expected, antibodies to ADA1 were able to precipitate ADA1 from wild-type but not from ⌬ada1 extracts and preimmune antisera were unable to precipitate ADA1 from either extract (Fig. 5B, ADA1 Western blot) . As shown in the top portion of Fig. 5B , ADA3 coimmunoprecipitated with ADA1, implying that ADA1 and ADA3 interact. Importantly, ADA3 was not precipitated in a ⌬ada1 extract or by preimmune serum, demonstrating that this interaction is specific and dependent on ADA1. Two other proteins probed in this experiment, TBP and TFIIB, did not coprecipitate with ADA1, indicating that they either do not interact with ADA1 or that an interaction is too weak to be detected.
To demonstrate that the other ADA gene products also interact either directly or indirectly with ADA1, antibodies to ADA2, GCN5, ADA5, and, as controls, to ADA1 and preimmune serum were cross-linked to protein A-Sepharose beads and used in immunoprecipitation experiments. As shown in Fig. 5C , antibodies to ADA2, GCN5, ADA5, and ADA1 but not to preimmune serum were able to precipitate ADA1 from wild-type extracts, demonstrating that there is an interaction between all of the ADA gene products. As verification that the protein coprecipitated by these antibodies is ADA1, the lower blot of Fig. 5C demonstrates that the protein is not precipitated from a ⌬ada1 extract. These results suggest that ADA1, ADA2, ADA3, GCN5, and ADA5 are all found in a single complex.
DISCUSSION
We report here the cloning, sequencing, and characterization of ADA1, which encodes a novel member of the ADA/ GCN5 complex. ADA1 encodes a 488-amino-acid protein. ada1 mutants display defects in transcription similar to those of ada5 mutants and broader than those found in ada2, ada3, and gcn5 mutants. Notably, mutations in ADA2, ADA3, and GCN5 do not affect transcription from the ADH1 promoter, while mutations in ADA1 and ADA5 decrease the activity of this reporter approximately fivefold. Indeed, since the activator that was used in the ADA screen, GAL4-VP16, was overexpressed by using the ADH1 promoter, it was initially thought that ADA1 was totally unrelated to ADA2, ADA3, and GCN5 because resistance could arise from a reduction in the amount of GAL4-VP16 produced. On the other hand, all ada mutants display similar decreases in transcription from GCN4-dependent promoters. Importantly, activity from the dAdT reporter was not reduced in a ⌬ada1 strain, demonstrating that not all transcription is dependent on ADA1. It has been proposed that FIG. 5 . Coprecipitation experiments between ADA1 and other ADA proteins. (A) Whole-cell extracts from BWG1-7a (WT) or 1-7a⌬ada1 (⌬ada1) strains were fractionated on a Bio-Rex 70 column as described in Materials and Methods. Proteins were eluted stepwise in 250, 600 and 1,200 mM potassium acetate. Then, 20 g each of whole-cell extract (starting material), the flowthrough, and each of the elutions were assayed for ADA1 and ADA3 by Western blot analysis. Recombinant ADA1 (rec ADA1) was used as a control in the ⌬ada1 blot to determine the migration of ADA1 by SDS-PAGE. The band in the 600 mM elution in the ⌬ada1 extract is a background band that migrates slightly above that of ADA1. (B) Immunoprecipitations were performed on 1 ml of the 600 mM elution from the wild-type (wt) and ⌬ada1 extracts shown in panel A by using either protein A-Sepharose beads cross-linked to ADA1 antibody (␣ADA1) or preimmune serum (PI). Then, 100 l of the 600 mM elution (START) of wild-type and ⌬ada1 extracts as well as the precipitations was subjected to SDS-PAGE and immunoblotted with the antibodies to the indicated proteins (ADA3, ADA1, TFIIB, and TBP). The band below ADA1 corresponds to an uncross-linked immunoglobulin G heavy chain which was eluted off the beads and which cross-reacts with the secondary antibody. (C) Immunoprecipitations were performed on 1 ml of the 600 mM elution from the wild-type (wt) and the ⌬ada1 extracts shown in panel A. Protein A-Sepharose beads cross-linked to preimmune serum (PI) and antibodies to ADA2 (␣ADA2), GCN5 (␣GCN5), ADA5 (␣ADA5), and ADA1 (␣ADA1) were used for immunoprecipitations. Then, 250 l of the 600 mM elution from the extracts (START) as well as from each of the precipitations was subjected to SDS-PAGE and analyzed by Western blotting for the presence of ADA1. As in panel B, the band below ADA1 in the precipitation lanes corresponds to an immunoglobulin G heavy chain. Rec ADA1 refers to 5 ng of recombinant ADA1.
VOL. 17, 1997 ADA1 AND THE ROLES OF THE ADA/GCN5 COMPLEXthe dAdT UAS activates transcription because this DNA sequence by itself disrupts nucleosomes (31) . It is possible that disruption of chromatin by dAdT bypasses the need for the histone acetyl transferase activity of the ADA/GCN5 complex in transcription. Two classes of ADA genes. The similarity in transcription defects between ⌬ada1 and ⌬ada5 strains led us to test whether the strains had other phenotypes in common. We have determined that ⌬ada1 strains are auxotrophic for inositol and are Spt Ϫ , two phenotypes described for ada5 mutants (45) . Furthermore, both ADA1 and ADA5 are in the TBP class of SPTs, not the histone class. This is in agreement with previous genetic and biochemical data and suggests a link between the functions of the ADA/GCN5 complex and TBP (2, 37). Controls consisting of representative mutants of the ADA2, ADA3, and GCN5 class of ADAs are neither auxotrophic for inositol nor Spt Ϫ . Thus, the ADA genes can be separated into two distinct classes based on three criteria: transcriptional reporters that are affected, inositol auxotrophy, and Spt phenotype.
The five ADA gene products form a complex. With two different classes of ADA genes, it seemed possible that two different complexes may be formed. Previously, it has been shown that ADA2, GCN5, and ADA3 form a complex in vitro (2, 29) . Also, various individual interactions between these three ADA proteins have been demonstrated in vivo (29, 38) . Therefore, it is clear that components of one of the classes form a complex. Interestingly, an interaction between ADA3 and ADA5 has also been demonstrated (37) , indicating a possible interaction between members of different classes of ADAs. Here we present evidence that all five ADA proteins bind together in a complex by two methods. First, we demonstrate that the five proteins remain together throughout an approximately 2,880-fold purification over four successive columns. In each of these columns, the ADA proteins eluted with identical profiles (Fig. 3 and 4) (56) . Second, we demonstrate, using immunoprecipitation experiments, specific interactions between ADA1 and each of the other ADA proteins (Fig. 5) . These two lines of evidence, taken together, strongly support a model in which all five ADA proteins form a complex in vivo.
The elution profile of the ADA proteins through the Superose 6 column indicates that the complex migrates with a molecular mass of approximately 2 MDa. This is much larger than the sum of the molecular masses of the five known individual subunits, suggesting that there may be other components that have yet to be identified or that the known components are present as multimers. Many other transcription factors have been shown to be associated in large-molecular-weight complexes, such as the TFIID complex, the SWI/SNF complex, and the holoenzyme complex. One possibility is that the ADA proteins could be part of one of these complexes. However, probing the partially purified ADA fractions with antibodies to TBP, Pol II, SWI3, and various SRBs demonstrated that these proteins do not peak with the ADA proteins (56) . Thus, the ADA/GCN5 complex may be distinct and novel.
In all the purification steps performed, all five ADA proteins cofractionate. This cofractionation is not limited to the ADAs in the 600 mM potassium acetate elution of the initial Bio-Rex 70 column but extends also to the ADAs in the flowthrough and 1,200 mM potassium acetate elutions (28, 56) . Thus, although we cannot rule out the formal possibility that ADA1 and ADA5 may form an alternate complex without the other ADAs, we have not found any evidence of this, and it seems more likely that all five ADA proteins are always associated.
It has recently been shown that a Tetrahymena GCN5 complex contains a protein that cross-reacts with antibody to ADA1 (9) . Also, human homologs of ADA2 and GCN5 have been isolated, and these homologs have been demonstrated to interact with each other (13) . These data suggest that the ADA/GCN5 complex is evolutionarily conserved.
One complex with two separate functions? As mentioned before, it has been determined that GCN5 functions as a histone acetyltransferase (10) and can acetylate free histone H3 in vitro. However, it is unable to acetylate whole nucleosomes. Thus, one function proposed for the other ADAs in the complex is to alter the conformation of either GCN5 or of nucleosomes, allowing the acetylation of whole nucleosomes (47) . We have demonstrated here that there are at least five ADA proteins in the ADA/GCN5 complex and that they can be separated into two distinct classes. We propose that the ADA proteins of one class, ADA2, ADA3, and GCN5, function together to acetylate nucleosomes, resulting in the clearing away of repressive nucleosomes from some promoters. The ADAs of the other class, ADA1 and ADA5, have an additional function. This is supported by the observation that ada1 and ada5 mutants have more pronounced phenotypic defects than ada2, ada3, and gcn5 mutants. If GCN5-dependent acetylation of histones was the sole function of the ADA/GCN5 complex, one would not expect to observe any ada mutants with phenotypes more severe than those of ⌬gcn5 mutants.
The proposed second function of the ADA/GCN5 complex has not been defined yet. One possibility is that GCN5 is not the only histone acetyltransferase in the ADA complex and that there is a second one that interacts with ADA1 and ADA5. On the other hand, it is fascinating that both ADA1 and ADA5, but not the other ADAs, are in the TBP class of SPTs.
Recently, it has been demonstrated that some strains with mutations in SPT15, which encodes TBP, are resistant to GAL4-VP16 toxicity (37) . It is extremely interesting to speculate, therefore, that the function of this second class of ADAs may be to interact with basal factors, possibly TBP. The ADA/ GCN5 complex may be brought to promoters through interactions between activators and ADA2 (2, 39, 55) and ADA5 (37) . Once there, the ADA2, ADA3, and GCN5 class of ADAs may function to acetylate nucleosomes, opening up the promoter region, while the ADA1 and ADA5 class of ADAs recruit TBP and possibly other basal factors to bind to the TATA box. The observation that ⌬ada1 or ⌬ada5 strains display broader defects than ⌬ada2, ⌬ada3, or ⌬gcn5 strains, combined with the observation that ⌬ada3 and ⌬ada5 strains do not display phenotypes more severe than ⌬ada5 strains (37) , suggests the following. Disrupting a member of the ADA2, ADA3, and GCN5 class of ADA will not disrupt the activity of the ADA1 and ADA5 class, whereas disrupting ADA1 or ADA5 may disrupt the activity of the entire ADA/ GCN5 complex.
It should be mentioned that TBP is not present in our partially purified ADA fractions and is not immunoprecipitated by ADA antibodies (Fig. 3 and 4) . However, other groups have demonstrated such interactions (2, 48) , and it is possible that TBP is not a stably bound component of the ADA/GCN5 complex but rather is only transiently associated, i.e., only when bound to DNA or when activators are bound to the ADA complex. Alternatively, it is possible that the ADAs in the 1,200 mM potassium acetate fraction from the Bio-Rex 70 column have different properties from the ADAs in the 600 mM fraction which we have been studying. Indeed, it has recently been reported that several ADA/GCN5 complexes may exist in yeast (48) . It will be interesting to determine whether the ADAs in the 1,200 mM potassium acetate fraction may be bound to TBP or other basal factors.
